Medical Devices & Lifesciences
Innovation governed by design control, risk management and a device history that regulators can inspect at any time.
The Nature of the Medical Devices & Lifesciences Industry
- →Development under FDA 21 CFR Part 820, EU MDR/IVDR and ISO 13485, where the design history file, risk file and device master record are mandatory outputs of engineering.
- →Products combining mechanics, electronics, software as a medical device, biologics and consumables, each with its own regulatory pathway.
- →Post-market surveillance obligations: complaints, adverse events, UDI reporting and field actions feed directly back into design and risk assessment.
- →Long approval cycles and high cost of change, which makes early-phase decisions disproportionately valuable.
Typical Challenges in Innovation and New Product Development
Design control executed in documents
Design inputs, outputs, verification and validation are often tracked in spreadsheets and Word files. Building the traceability matrix for a submission becomes a months-long manual effort with real audit risk.
Risk management kept separate from design
ISO 14971 hazard analyses are maintained apart from the product structure, so a design change does not automatically trigger reassessment of the associated risk controls.
Quality and engineering disconnection
CAPAs, nonconformances and complaints live in the QMS while the change lives in engineering, causing duplicate records and slow closure.
Regulatory divergence across markets
The same device requires different technical documentation, labelling and UDI data per region, multiplying maintenance effort.
Supplier and material compliance
Biocompatibility, sterilization and material declarations must be current and traceable for every supplied component.
How PLM and AI Have Benefitted Medical Devices & Lifesciences Companies
Design control as a living structure
PLM links requirements, design outputs, risk controls, verification and validation records so that the design history file and traceability matrix are always current, turning submission preparation into an export rather than a project.
Integrated risk and change management
When a design element changes, the linked hazards, risk controls and verification evidence are flagged automatically, ensuring reassessment happens by process rather than by memory.
Closed-loop quality
Complaints, CAPAs and nonconformances connect directly to the part, batch and change record, shortening investigation and closure time and producing defensible evidence at inspection.
AI for regulatory documentation
Language models draft and cross-check technical documentation, compare files against MDR and FDA guidance, and detect gaps or inconsistencies in traceability before a notified-body review.
AI in post-market surveillance
Machine learning classifies complaint and adverse-event text at scale, detecting emerging signals far earlier than manual review and feeding them into risk files and design improvements.
Outcomes We See in Medical Devices & Lifesciences
- ✓Submission-ready design history and traceability at any moment
- ✓Risk files that stay synchronized with design changes
- ✓Shorter CAPA and complaint closure cycles
- ✓Earlier detection of post-market signals
Discuss Your Medical Devices & Lifesciences Initiative
Tell us about your product development and PLM priorities and we will share how comparable medical devices & lifesciences organizations have approached them.